Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
HALO
#982
Halozyme Therapeutics, Inc. - Common Stock
75.0
5
USD
-0.01%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-1.39%
Monthly Change
+4.80%
6 month change
+4.77%
Year Change
+12.35%
Previous Close
76.1
1
Open
75.0
5
Low
75.0
5
High
75.0
5
Volume
231
Markets
US Stock Market
Healthcare
Biotechnology
HALO
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
135.28 M
137.7 M
135.37 M
126.82 M
123.15 M
118.02 M
118.61 M
Valuation ratios
Enterprise value
6.03 B
6.3 B
8.73 B
6.12 B
7.28 B
9.95 B
11.17 B
Price to earnings ratio
46.93
14.68
38.28
17.8
13.94
26.29
28.22
Price to sales ratio
22.58
13.31
11.74
6.05
6.09
5.97
6.58
Price to cash flow ratio
108.95
19.71
32.28
12.91
12.92
12.8
14.63
Price to book ratio
40
29.97
45.65
59.87
17.01
170.83
8.96
Enterprise value to EBITDA ratio
40.85
22.57
31.88
17.56
12.96
20.71
21.27
Profitability ratios
Return on assets %
0.22
0.36
0.11
0.16
0.22
0.13
0.06
Return on equity %
0.85
2.04
1.19
3.36
1.22
6.49
0.68
Return on invested capital %
142.63
109.99
102.11
76.15
106.21
57.5
27.77
Gross margin %
83.79
81.64
78.9
76.8
84.3
83.62
78.97
Operating margin %
53.91
62.24
40.53
40.71
54.32
33.58
48.98
EBITDA margin %
55.14
62.91
41.51
42.04
55.33
34.4
50.1
Net margin %
48.24
90.84
30.62
33.96
43.74
22.69
39.83
Liquidity ratios
Quick ratio
1.17
7.45
4.88
5.5
6.78
3.66
2.33
Current ratio
1.32
7.91
5.65
6.64
7.8
4.66
2.76
Inventory turnover
0.96
1.42
1.81
1.69
1.18
1.3
0.48
Asset turnover
0.47
0.53
0.45
0.46
0.53
0.55
0.14
Solvency ratios
Debt to assets ratio
0
0.71
0.81
0.86
0.73
0.85
0.72
Debt to equity ratio
0
4
8.79
17.89
4.14
43.89
8.81
Long term debt to total assets ratio
0
0.71
0.81
0.86
0.73
0.85
—
Long term debt to total equity ratio
0
4
8.79
17.89
4.14
43.89
—
Per share metrics
Operating cash flow per share
0.39
2.04
1.71
2.9
3.7
5.26
5.5
EBIT per share
1.02
1.88
1.9
2.52
4.26
3.79
4.16
EBITDA per share
1.04
1.9
1.95
2.6
4.34
3.88
4.27
Total debt per share
2.81
5.97
10.71
11.17
11.63
17.29
15.76
Cash per share
2.6
5.05
2.58
0.88
0.9
1.08
2.52
Net current asset value per share
3.92
6.31
5.26
5.56
8.39
6.66
8.16
Tangible book value per share
1.07
1.34
1.21
0.62
2.81
0.39
1.79
Working capital per share
0.94
5.51
4.33
4.72
7.31
5.23
5.21
Book value per share
1.07
1.34
1.21
0.62
2.81
0.39
1.79
News
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
TG Therapeutics Stock Is On A Hot Streak: Why It's Up 70% And Climbing
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans
Implied Volatility Surging for Halozyme Therapeutics Stock Options
Halozyme Therapeutics: Royalty King (NASDAQ:HALO)
Company News for May 13, 2026
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up
Halozyme Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:HALO) 2026-05-11
Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say